Literature DB >> 15951330

Regulation of urokinase receptor expression by phosphoglycerate kinase is independent of its catalytic activity.

Sreerama Shetty1, Malathesha Ganachari, Ming-Cheh Liu, Ali Azghani, Harish Muniyappa, Steven Idell.   

Abstract

Posttranscriptional regulation of urokinase-type plasminogen activator receptor (uPAR) mRNA involves the interaction of a uPAR mRNA coding region sequence with phosphoglycerate kinase (PGK), a 50-kDa uPAR mRNA binding protein. PGK catalyzes a reversible transfer of a phosphoryl group from 1,3-biphosphoglycerate to ADP in the glycolytic pathway. Our previous studies showed that overexpression of PGK in uPAR-overproducing H157 lung carcinoma cells results in decreased cytoplasmic uPAR mRNA and cell surface uPAR protein expression through destabilization of the mRNA. In order to determine the role of PGK enzymatic activity on uPAR mRNA stability we mutated PGK by changing amino acid P204H and amino acid D219A. The mutant proteins were expressed in Epicurian coli BL21 cells, and the purified proteins were analyzed for PGK activity. We found that mutation of amino acid P204H and D219A reduced PGK activity by 99 and 83%, respectively. By gel mobility shift and Northwestern assay, we found that the mutant proteins were able to bind to uPAR mRNA as effectively as wild-type PGK. Overexpression of mutant, inactive PGK in H157 cells reduced cell surface uPAR protein as well as uPAR mRNA expression. Run-on transcription analysis indicated that overexpression of mutant PGKs fails to alter the rate of synthesis of uPAR mRNA, whereas transcription chase experiments demonstrated that both mutants and wild-type PGK reduce the stability of the uPAR mRNA transcripts to a similar extent. Overexpression of mutant PGK also inhibited the rate of DNA synthesis and the invasion-migration ratio. These results demonstrate that uPAR mRNA binding activity as well as PGK-mediated regulation of uPAR mRNA are independent of PGK enzymatic activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951330     DOI: 10.1152/ajplung.00319.2004

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  6 in total

1.  Regulation of urokinase expression at the posttranscription level by lung epithelial cells.

Authors:  Shwetha K Shetty; Amarnath S Marudamuthu; Daniel Abernathy; Rashmi S Shetty; Praveenkumar Shetty; Jian Fu; Steven Idell; Yashodhar P Bhandary; Honglong Ji; Ming-Cheh Liu; Sreerama Shetty
Journal:  Biochemistry       Date:  2011-12-23       Impact factor: 3.162

2.  Ectopic expression of Pokkali phosphoglycerate kinase-2 (OsPGK2-P) improves yield in tobacco plants under salinity stress.

Authors:  Rohit Joshi; Ratna Karan; Sneh L Singla-Pareek; Ashwani Pareek
Journal:  Plant Cell Rep       Date:  2015-09-25       Impact factor: 4.570

Review 3.  PGK1-mediated cancer progression and drug resistance.

Authors:  Yu He; Yang Luo; Dan Zhang; Xixi Wang; Peng Zhang; Haocheng Li; Samina Ejaz; Shufang Liang
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

4.  Urokinase receptor expression involves tyrosine phosphorylation of phosphoglycerate kinase.

Authors:  Praveenkumar Shetty; Thirunavukkarasu Velusamy; Yashodhar P Bhandary; Ming C Liu; Sreerama Shetty
Journal:  Mol Cell Biochem       Date:  2009-09-26       Impact factor: 3.396

5.  Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.

Authors:  S Sun; X Liang; X Zhang; T Liu; Q Shi; Y Song; Y Jiang; H Wu; Y Jiang; X Lu; D Pang
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

6.  Glycolysis, tumor metabolism, cancer growth and dissemination. A new pH-based etiopathogenic perspective and therapeutic approach to an old cancer question.

Authors:  Khalid O Alfarouk; Daniel Verduzco; Cyril Rauch; Abdel Khalig Muddathir; H H Bashir Adil; Gamal O Elhassan; Muntaser E Ibrahim; Julian David Polo Orozco; Rosa Angela Cardone; Stephan J Reshkin; Salvador Harguindey
Journal:  Oncoscience       Date:  2014-12-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.